91丝瓜视频
The Major Partnerships funding program offers two distinct funding streams and flexibility to accommodate the versatile nature of interactions in the translational and commercialization space. The program supports co-funding of D2R researchers and associated projects with different types of partners by providing a 1:1 leverage or greater (depending on leveraging) for specific projects. The program accepts proposals at any time.
The review and selection process for the Major Partnerships program follows two stages:
- Letter of Intent review: This initial step ensures that proposed projects are in alignment with D2R鈥檚 mission. Approved projects are invited to submit a full application.
- Full application review: Projects proceed to detailed evaluation and external scientific merit review, coordinated by D2R or an external co-funder. D2R's Research Steering Committee听reviews the reviewer evaluations, the project's relevance to D2R's strategic goals and the program budget in its funding decisions.
Major Partnerships Awards
| Principal Investigator | Title | Partner(s) |
|---|---|---|
| Nicolas Moitessier | Machine learning models for the design of RNA therapeutics: Development of experimental data | Deep Genomics |
| J枚rg Fritz | Rapid antigen identification platform for vaccine development | M茅dicament Qu茅bec, RNA Technologies and Therapeutics Inc., AReNA, NovoArc GmbH,听Victor Phillip Dahdaleh Institute for Genomic Medicine |
| Masad Damha | Therapeutic development of the CRISPR-Cas12a gene editing system | Eli Lilly |
| Martin Schmeing | mRNA Structure Determination to Advance Therapeutic mRNA Design | Moderna |
Machine learning models for the design of RNA therapeutics: Development of experimental data
In partnership with Deep Genomics, this project aims to speed up the discovery of RNA-based medicines using artificial intelligence. By combining lab-generated data with computational models, the team will lay the foundation for machine learning tools that could transform how RNA therapies are developed.
Principal Investigator: Nicolas Moitessier (91丝瓜视频)
Co-Investigator: Anthony Mittermaier (91丝瓜视频)
Partner(s): Deep Genomics
Project duration: 18 months
Relevant D2R Axes: RNA Therapeutics听(Axis 2)
Rapid antigen identification platform for vaccine development
Announced at BIO International 2025, this project, co-funded by M茅dicament Qu茅bec, RNA Technologies and Therapeutics Inc., AReNA, NovoArc GmbH and the Victor Phillip Dahdaleh Institute, represents a major collaborative effort in the development of next-generation mRNA vaccines. The project will build a rapid preclinical platform to identify vaccine targets and test new mRNA vaccine technologies, enabling researchers to respond faster and more effectively to emerging infectious diseases. The project involves collaborations with academic and industry partners to validate the platform鈥檚 utility in real-world scenarios.
Principal Investigator: J枚rg Fritz (91丝瓜视频)
Co-Investigators: Silvia Vidal (91丝瓜视频), David Langlais (91丝瓜视频)
Collaborators: David J. Kelvin (Dalhousie University), Alyson A. Kelvin (University of Calgary), Mohamad-Gabriel Alameh (RNA Technologies and Therapeutics), David Wurm (NovoArc GmbH)
Partners: M茅dicament Qu茅bec, RNA Technologies and Therapeutics Inc., AReNA, NovoArc GmbH, Victor Phillip Dahdaleh Institute for Genomic Medicine
Project duration: 26 months
Relevant D2R Axes: RNA Therapeutics (Axis 2)
Therapeutic development of the CRISPR-Cas12a gene editing system
This collaborative project between 91丝瓜视频, Eli Lilly and Wake Forest University involves nucleic acid chemistry and biology and student training aimed at enhancing the drug-like properties of RNA therapeutics. This project will build on chemical design principles, establish a RNA modification platform, and accelerate the development of CRISPR-Cas12a as a human gene therapy for curing genetic disorders.
Principal Investigator: Masad Damha (91丝瓜视频)
Partner(s): Eli Lilly & Company
Collaborator(s): Gagnon Keith (Wake Forest University Medical Center)
Project duration:听Two-years
Relevant D2R Axes: RNA Therapeutics (Axis 2)
mRNA Structure Determination to Advance Therapeutic mRNA Design
mRNA technology has brought major medical breakthroughs, from anti-viral vaccines to new cancer treatments. A big remaining challenge is that mRNA is naturally fragile, making it harder use effectively in therapies. Scientists try to predict how mRNA folds into its 3D shape, since this folding affects its stability, but current tools aren鈥檛 yet reliable, partly because it鈥檚 not known what full mRNA molecules really look like in 3D. By using powerful imaging techniques called atomic force microscopy and crystallography, this porject will capture the detailed 3D structure of a full, stabilized mRNA molecule, to help improve the design of mRNA medicines.
Principal Investigator:听Martin Schmeing (91丝瓜视频)
Co-Investigators:听Hanadi Sleiman (91丝瓜视频)
Collaborator(s): Mihir Mektar (Moderna)
Partner(s): Moderna
Project duration:听Two-years
Relevant D2R Axes: RNA Therapeutics (Axis 2)
